Crisis stabilization services; facilities licensed by DBHDS, nursing homes.
Do you support it?
Want to know if it passes?
We'll email you when SB 568 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 568.
You're tracking SB 568
We'll email you the moment it moves.
SB 568 — Crisis stabilization services; facilities licensed by DBHDS, nursing homes.
Last action — Acts of Assembly Chapter text (CHAP0513)
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
✓Passed Senate
-
✓Passed House of Delegates
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced January 10, 2024. Enacted.
Signed by Governor Glenn Youngkin (Republican) on April 04, 2024.
Prognosis
Where this bill stands today.
Odds of enactment
HighHow often bills like it became law.
-
Enacted
Current position in the legislative process.
-
1 sponsor
1 primary, 0 co-sponsors signed on.
-
Cleared a recorded vote
Passed 7 recorded votes so far.
Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.
Summary
Crisis stabilization services; facilities licensed by Department of Behavioral Health and Developmental Services; nursing homes; dispensing and administration of drugs; emergency. Permits facilities licensed by the Department of Behavioral Health and Developmental Services that provide crisis stabilization services to maintain a stock of Schedules II through VI controlled substances necessary for immediate treatment of patients admitted to such facility. Under current law, maintenance of a stock of Schedule VI controlled substances is allowed under certain conditions, but a stock of Schedules II through V controlled substances may be maintained only if authorized by federal law and Board of Pharmacy regulations. The bill also allows automated drug dispensing systems and remote dispensing systems to be used by state facilities established pursuant to Title 37.2 (Behavioral Health and Developmental Services), facilities that provide crisis stabilization services, nursing homes, and other facilities authorized by the Board of Pharmacy that meet certain conditions. The bill contains an emergency clause, directs the Board of Pharmacy to adopt emergency regulations to implement the provisions of the bill, and is identical to HB 1336.
Bill Text
What changed in the latest version
461 added · 439 removedPlain-language change summary
The recent amendment to Bill SB 568 updated certain definitions within the Virginia Code regarding the handling of controlled substances. Specifically, the definition of "administer" now no longer includes "ingestion" as a method of application, which may impact how drugs are dispensed in various medical settings. These changes are important as they aim to clarify regulatory language, ensuring safer practices and compliance in the administration of medications. This could help prevent misuse and streamline procedures for healthcare providers.
SESSION ENROLLED VIRGINIA ACTS OF ASSEMBLY ––-- 2024 SESSION CHAPTER E513 An Act to amend and reenact §§ 54.1-3401, 54.1-3423, and 54.1-3434.02 of the Code of Virginia, Nrelating Developmentalto Services;crisis stabilization services;
facilities licensed by Department of Behavioral Health and Developmental Services;
emergency.lemergency. HRalth and O [S 568] L Approved L Be it enacted by the General Assembly of Virginia:
E[S 1.568] Approved April 4, 2024 Be it enacted by the General Assembly of Virginia:
That1. §§ 54.1-3401, 54.1-3423, and 54.1-3434.02 of the Code of Virginia are amended and D ree§ 54.1-3401.
That §§ 54.1-3401, 54.1-3423, and 54.1-3434.02 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-3401.
"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.
"Advertisement" means all representations disseminated in any manner or by any means, other Bhanthan by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly6indirectly, the pur"Agent"purchase means an authorized person who acts on behalf of ordrugs at the direction of a manufacturEr, distributor, or dispenser.devices.
It "Agent" doesmeans notan includeauthorized aperson commonwho oracts contracton carrier,behalf publicof Ror warehouseman,at orthe employeedirection of thea carriermanufacturer, distributor, or warehouseman.dispenser.
It "Agent" does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.
"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, allincluding transactionthe information,storage, todispensing, provideor securitydistribution andof accountabilitydrugs forand suchthe drugs.trol,collection, control, and maintenance of "Biologicalall product"transaction meansinformation, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to theprovide prevention,security treatment,and oraccountability curefor ofsuch adrugs. disease or condition of human beings.
"Biosimilar""Biological product" means a biologicalvirus, producttherapeutic thatserum, istoxin, highlyantitoxin, similarvaccine, toblood, blood component or derivative, allergenic product, protein other than a specificchemically referencesynthesized biologicalpolypeptide, or analogous product, notwithstandingor minorarsphenamine differencesor inany clinicallyderivative inactiveof compounds,arsphenamine suchor thatany thereother aretrivalent noorganic hasarsenic beencompound, licensedapplicable asto the prevention, treatment, or cure of a biosimilardisease pursuantor tocondition 42of U.S.C.human beings.
§"Biosimilar" 262(k)means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in termsclinically ofinactive safety,compounds, purity,such andthat potencyatthere ofare no clinically meaningful differences between the product.reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C.
§ 262(k) in terms of safety, purity, and potency of the product.
"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity;
(ii) the creation of a partnership by a sole proprietor, the dissolution of aata owns partnership, or change in partnership composition;
"Co-licensed partner" means a person who, with at least one other person, has the right to engage in the manufacturing or marketing of a prescription drug, consistent with state and federal law.
engage in "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a of 8 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or of 8 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in expectation of receiving a valid prescription based on observed historical patterns of prescribing and dispensing;
For practitioners of medicine or osteopathy, "dispense" shall includes only include the of 8 provision of drugs by a practitioner to patients to take with them away from the practitioner's place of practice.
E "Dispenser" means a practitioner who dispenses.
Rof 8 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them;
E "Drug product" means a specific drug in dosage form from a known source of manufacture, whether by brand or therapeutically equivalent drug product name.
D "Electronic prescription" means a written prescription that is generated on an electronic application and is transmitted to a pharmacy as an electronic data file;
Schedule Schedules II through V pre"Facsimileprescriptions (FAX)shall prescription"be means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hardaccordance copywith form.21 C.F.R.
Part 1300.
"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy form.
S "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by 5 regulation designates as being the principal compound commonly used or produced primarily for u8e,use, and which is an immediate chemical intermediary used or likely to be used in the manufacture ofRaof a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.
"Label" means a display of written, printed, or graphic matter upon the immediate container of any article.
A requirement made by or under authority of this chapter that any word, statement, or otheryother information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article or is easily legible through the outside container or wrapper.
"Manufacture" means the production, preparation, propagation, conversion, or processing of any item regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container.
This term "Manufacture" does not include compounding.tancecompounding. or labeling or relabeling of its "Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a repackager.
"Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a repackager.
(ii) industrial hemp, as defined in § 3.2-4112, that is possessed by a person registered ispursuant possessedto bysubsection aA personof who§ holds3.2-4115 aor hemphis produceragent; license issued by the U.S.
Department(iii) ofindustrial hemp, as defined in § 3.2-4112, that Agricultureis pursuantpossessed toby 7a C.F.R.person who holds a hemp producer license issued by the U.S.
Department of Agriculture pursuant to 7 C.F.R.
"Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for per"Narcoticperitoneal drug"dialysis, meansand anysterile ofwater the following, whether produced directly or indirectlysaline byfor extractionirrigation. from substances of vegetable origin, or independently by means of chemical synthesis, or by a of 8 combination of extraction and chemical synthesis:
"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
of 8 "New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.
"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such of 8 drugs or medical supplies.
Show all 74 changed lines (34 more)
"Prescription drug" means any drug required by federal law or regulation to be dispensed onlEonly pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
N "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harveRtingharvesting of a controlled substance or marijuana.
"Proprietary medicine" means a completely compounded nonprescription drug in its unbroken, original package which does not contain any controlled substance or marijuana as defined in this chapter and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general public by or under the authority of the manufacturer or primary distributor, under a trademark, trade name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of of 8 this chapter and applicable federal law.
However, this definition shall "proprietary medicine" Eoesdoes not include a drug that is only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic, a drug that may be dispensed only upon prescription or the label of which bears substantially the statement "Warning –– may be habit-forming," or a drug intended for injection.
"Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or radionuclide generator that is intended to be used in the preparation of any such substance, but does not include drugs such as carbon-containing compounds or potassium-containing salts that include trace quantities of naturally occurring radionuclides.
The term "Radiopharmaceutical" also includes any biological product that is labeled with a radionuclide or intended solely to be labeled with a S radionuclide.
5 "Reference biological product" means the single biological product licensed pursuant to 42 U8S.C.U.S.C.
§ 262(a) against which a biological product is evaluated in an application submitted to the U.SRU.S. Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to 42 U.S.C.
Food and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to U.S.C.
"Remote dispensing system" means a profile-driven automated drug dispensing system that performs operations or activities relative to the storage, packaging, labeling, or dispensing of medications employing bidirectional audio-visual technology to facilitate pharmacist communication with a patient, authorized agent of the patient, or person licensed to administer drugs, and collects, controls, and maintains all information online.
"Tetrahydrocannabinol" means any naturally occurring or synthetic tetrahydrocannabinol, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation and any preparation, mixture, or substance containing, is or mixed or infused with, any detectable amount of tetrahydrocannabinol.
Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book." "Third-party logistics provider" means a person that provides or coordinates warehousing of or other logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesaleerwholesale distributor, or dispenser of the drug or device but does not take ownership of the product or have responsibility for directing the sale or disposition of the product.
"Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party logistics provider, engaged in the business of (i) selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer and (ii) delivering Schedule VI subjectprescription devices to anythe stateultimate user or localconsumer taxpursuant byto reason of this definition.to § 54.1-3415.1.
No person shall be "Wholesalesubject distribution" means (i) distribution of prescription drugs to personsany otherstate than consumers of 8 or patientslocal andtax (ii)by deliveryreason of Schedulethis VIdefinition. prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.
"Wholesale distribution" means (i) distribution of prescription drugs to persons other than consumers or patients and (ii) delivery of Schedule VI prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1, subject to the exemptions set forth in the federal Drug Supply Chain Security Act.
The Board shall register an applicant to manufacture or distribute controlled substances included of 8 in Schedules I through V unless it determines that the issuance of that registration would be inconsistent with the public interest.
The shelter shall of 8 maintain a copy of the approved list of drugs and biological products, written protocols for administering, and training records of those persons administering drugs and biological productEproducts on the premises of the shelter.
The Board may register a facility, as defined in § 37.2-100, that provides crisis stabilization unit established pursuant to § 37.2-500 or 37.2-601 services and is licensed by the Department of BeRavioralBehavioral Health and Developmental Services to.
Such facility may maintain a stock of Schedule Schedules II through VI controlled substances necessary for immediate treatment of patients admitted to the crisis stabilization unit such facility, which may be accessed and administered by a nurse person licensed to administer drugs pursuant to a written or oral order of a prescriber in the absence of a prescriber.
L G.
The Board may register an entity at which a patient is treated by the use of instrumentatEoninstrumentation and diagnostic equipment through which images and medical records may be transmitted electronically for the purpose of establishing a bona fide practitioner-patient relationship and is prescribed Schedule Schedules II through VI controlled substances when such prescribing is in compliance with federal requirements for the practice of telemedicine and the patient is not in the physical presence of a registrationpractitioner shallregistered be issued, the Board shall consider (i) the factors listed in subsection A, (ii) whether there is a documented need for such registration, and (iii) whether the issuance of the registration is consistent with the publicU.S. interest.
Drug Enforcement Administration.
In determining whether the of 8 registration shall be issued, the Board shall consider (i) the factors listed in subsection A, (ii) whether there is a documented need for such registration, and (iii) whether the issuance of the registration is consistent with the public interest.
Applications for controlled substances registration certificates and renewals thereof shaSlshall be made on a form prescribed by the Board and such applications shall be accompanied by a fee in an amo5ntamount to be determined by the Board.
8 I.
Upon (i) any change in ownership or control of a business, (ii) any change of location ofRtheof the controlled substances stock, (iii) the termination of authority by or of the person named as the responsible party on a controlled substances registration, or (iv) a change in the supervising practitioner, if applicable, the registrant or responsible party shall immediately surrender the registration.
The registrant shall, within 14 days following surrender of a registration, file a new application and, if applicable, name the new responsible party or supervising practitioner.
file a new application and, if § 54.1-3434.02.
Drugs are placed in the automated drug dispensing system or remote dispensing system in a such hospital, nursing home, or facility and are under the control of a pharmacy providing services to the hos2.hospital, nursing home, or facility;
2.
provided,4. as evidenced by written policies and procedures, for (i) preventing unauthorized access, (ii) complying with federal and state regulations on prescribing and dispensing controlled substances, (iii) maintaining patient confidentiality, and (iv) assuring ensuring compliance with the requirements of this section;
Adequate security for automated drug dispensing systems or remote dispensing systems is provided, as evidenced by written policies and procedures, for (i) preventing unauthorized access, (ii) complying with federal and state regulations on prescribing and dispensing controlled substances, (iii) maintaining patient confidentiality, and (iv) assuring ensuring compliance with the requirements of this section;
The task of filling and stocking of drugs into an automated drug dispensing such system shall be performed by a pharmacist or a registered pharmacy technician, who shall be an employee of the provider pharmacy and shall bestbe or properly trained in accordance with established standards set forth in a policy and procedure manual of 8 maintained by the provider pharmacy.
The pharmacist-in-charge in a pharmacy located within a hospital, nursing home, or facility or the pharmacist-in-charge of any outside pharmacy providing pharmacy services to a hospital, nursing home, or facility shall be responsible for establishing procedures for (i) periodically inspecting and auditing of 8 automated drug dispensing systems and remote dispensing systems to assure ensure the proper storage, security, and accountability for all drugs placed in and removed from automated drug dispensing systems and remote dispensing systems, and (ii) reviewing the operation and maintenance of automated drug dispensing systems and remote dispensing systems.
Show all 74 changed rows (34 more)
View plain text versions (4)
- CHAP0513 View text Current pdf April 04, 2024
- SB568ER View text pdf March 04, 2024
- Committee Substitute Committee substitute printed 24106466D-S1 pdf February 08, 2024
- Prefiled Prefiled and ordered printed with emergency clause; offered 01/10/24 24102020D pdf January 10, 2024
Action History
-
Acts of Assembly Chapter text (CHAP0513)
-
Approved by Governor-Chapter 513 (effective 4/4/24)
-
Governor's Action Deadline 11:59 p.m., April 8, 2024
-
Enrolled Bill Communicated to Governor on March 11, 2024
-
Signed by President
-
Signed by Speaker
-
Impact statement from DPB (SB568ER)
-
Bill text as passed Senate and House (SB568ER)
-
Enrolled
-
House amendments agreed to by Senate (39-Y 0-N)
-
VOTE: Block Vote Passage (98-Y 0-N)
-
Passed House with amendments BLOCK VOTE (98-Y 0-N)
-
Engrossed by House as amended
-
Committee amendments agreed to
-
Read third time
-
Read second time
-
Reported from Health and Human Services with amendment(s) (22-Y 0-N)
-
Referred to Committee on Health and Human Services
-
Read first time
-
Placed on Calendar
-
Impact statement from DPB (SB568S1)
-
Passed Senate (40-Y 0-N)
-
Constitutional reading dispensed (40-Y 0-N)
-
Engrossed by Senate - committee substitute SB568S1
-
Committee substitute agreed to 24106466D-S1
-
Reading of substitute waived
-
Read second time
-
Constitutional reading dispensed (40-Y 0-N)
-
Committee substitute printed 24106466D-S1
-
Reported from Education and Health with substitute (15-Y 0-N)
-
Senate subcommittee amendments and substitutes offered
-
Assigned Education and Health Sub: Health Professions
-
Impact statement from DPB (SB568)
-
Referred to Committee on Education and Health
-
Prefiled and ordered printed with emergency clause; offered 01/10/24 24102020D
Sponsors
- R. Creigh Deeds · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 147 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (147)
147 members have not signed on to this bill.
Show all 147 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 39 | 0 | 0 | 1 |
| Total | 39 | 0 | 0 | 1 |
| % of votes cast | 98% | 0% | 0% | 3% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Yea |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Yea |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Not Voting |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 97 | 0 | 0 | 2 |
| Total | 97 | 0 | 0 | 2 |
| % of votes cast | 98% | 0% | 0% | 2% |
How each member voted (99)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 22 | 0 | 0 | 0 |
| Total | 22 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (22)
| Member | Party | Vote |
|---|---|---|
| C.E. Cliff Hayes, Jr. | — | Yea |
| Charniele L. Herring | — | Yea |
| Debra D. Gardner | — | Yea |
| Ennis, N. Baxter | — | Yea |
| H. Otto Wachsmann, Jr. | — | Yea |
| Higgins, Geary | — | Yea |
| Irene Shin | — | Yea |
| Joshua G. Cole | — | Yea |
| Kannan Srinivasan | — | Yea |
| Kathy K.L. Tran | — | Yea |
| M. Keith Hodges | — | Yea |
| Marcia S. "Cia" Price | — | Yea |
| Mike A. Cherry | — | Yea |
| Orrock, Robert D., Sr. | — | Yea |
| Owen, David | — | Yea |
| Patrick A. Hope | — | Yea |
| Phillip A. Scott | — | Yea |
| Rodney T. Willett | — | Yea |
| Rozia A. Henson, Jr. | — | Yea |
| Sickles, Mark D. | — | Yea |
| Taylor, Kim A. | — | Yea |
| Wendell S. Walker | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 40 | 0 | 0 | 0 |
| Total | 40 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Yea |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Yea |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 40 | 0 | 0 | 0 |
| Total | 40 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Yea |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Yea |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 15 | 0 | 0 | 0 |
| Total | 15 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (15)
| Member | Party | Vote |
|---|---|---|
| Barbara A. Favola | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| David R. Suetterlein | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| Jennifer B. Boysko | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark J. Peake | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Tara A. Durant | — | Yea |
| Todd E. Pillion | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 40 | 0 | 0 | 0 |
| Total | 40 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Yea |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Yea |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Yea |
Subjects
Frequently asked questions
- What does SB 568 do?
- Crisis stabilization services; facilities licensed by Department of Behavioral Health and Developmental Services; nursing homes; dispensing and administration of drugs; emergency. Permits facilities licensed by the Department of Behavioral Health and Developmental Services that provide crisis stabilization services to maintain a stock of Schedules II through VI controlled substances necessary for immediate treatment of patients admitted to such facility. Under current law, maintenance of a stock of Schedule VI controlled substances is allowed under certain conditions, but a stock of Schedules II through V controlled substances may be maintained only if authorized by federal law and Board of Pharmacy regulations. The bill also allows automated drug dispensing systems and remote dispensing systems to be used by state facilities established pursuant to Title 37.2 (Behavioral Health and Developmental Services), facilities that provide crisis stabilization services, nursing homes, and other facilities authorized by the Board of Pharmacy that meet certain conditions. The bill contains an emergency clause, directs the Board of Pharmacy to adopt emergency regulations to implement the provisions of the bill, and is identical to HB 1336.
- Who sponsors SB 568?
- SB 568 is sponsored by R. Creigh Deeds.
- What is the current status of SB 568?
- This bill has been enacted into law. Introduced January 10, 2024. Enacted.
- Where can I track SB 568?
- Track SB 568 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 568
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 568
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →